One could also ask why institutions own so few shares compared to other biotechs. Do they know something? Remember, much of mgmt's shares were either aquired years ago or as options. The institutional holdings should have you scratching your head.
Finally, the OXiGENE team spent agreat deal of time at ASCO meeting with potential partners for our clinical programs. The meetings were very productive, and ranged from talks with specialists interested in orphan drug marketing, to regional firms looking to enter the oncology space, to global pharmaceutical companies interested in finding a new later-phase addition to their oncology franchise. With data from two randomized controlled studies and worldwide rights available for license, we believe that ZYBRESTAT is now an asset uniquely suited for collaboration. We intend to take advantage of the interest shown in our VDA assets and continue to advance these ongoing discussions. Overall, I believe our ASCO experience in 2011 was agreat success. The data we presented and the discussions we participated in reinforced our belief that our VDA assets are backed by a substantial and growing body of data that clearly suggests their safety and activity, and that there is significant interest from potential partners. One of our tasks now is to finalize clear development plans that provide the greatest likelihood of success, not only clinically, but commercially for our later-stage assets.